Skip to content
OpenCapital
Get started

Summit Therapeutics SMMT Q1 2025 earnings

Reported May 1, 2025 · After market close

Diluted EPS-$0.09Beat by $0.00
EPS estimate-$0.09

Next report

Aug 10, 2026 (In 4 weeks)
Revenue estimate$108.8K
EPS estimate-$0.26

Financials

Q1 2025

Income statement

See full
Net income-$62.9M-44.7%
EPS (diluted)-$0.09-50.0%

Balance sheet

See full
Cash & equivalents$7.7M+83.3%
Total debt$6.5M-94.1%
Total equity$344.3M+679%
Total assets$383.8M+117%

Cash flow

See full
Operating cash flow-$61.2M-103%
CapEx$422.0K+10,450%
Free cash flow-$61.6M-104%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$14.23B+390%
Enterprise value$14.23B+372%

Returns & leverage

See full
Return on equity-123.9%-6.0pp
Debt / equity0×-2.5×
Current ratio10.6×+3.7×

Versus estimates

Diluted EPS

Q1 2026-$0.24Beat by $0.09Q4 2025-$0.29Miss by $0.19Q3 2025-$0.31Miss by $0.13Q2 2025-$0.76Miss by $0.67
Q1 2025-$0.09Beat by $0.00
Q4 2024-$0.08Beat by $0.00

Ask the moment Summit Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Summit Therapeutics report Q1 2025 earnings?
Summit Therapeutics (SMMT) reported Q1 2025 earnings on May 1, 2025 after market close.
What were Summit Therapeutics's Q1 2025 revenue and EPS?
Summit Therapeutics reported diluted EPS of $-0.09 for Q1 2025.
Did Summit Therapeutics beat estimates in Q1 2025?
EPS beat the consensus estimate of $-0.09 by $0.00.
How did Summit Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 50.0% from $-0.06.
Where can I find Summit Therapeutics's Q1 2025 SEC filings?
You can read the 10-Q periodic report (0001599298-25-000089) directly on SEC EDGAR. The filing index links above go to sec.gov.